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ABSTRACT
Lipid bodies are non-membrane bound, lipid-rich 
cytoplasmic inclusions that form in diverse cell types. 
Characteristically, lipid body numbers increase when 
eosinophils and other leukocytes are participating in 
inflammatory processes. Moreover, lipid bodies are 
numerous in other sites active in eicosanoid formation, 
such as the amnion epithelium at parturition. Our 
interests in lipid bodies relate to the roles that these 
structures play in arachidonate metabolism by 
eosinophils and other leukocytes involved in 
inflammation. Findings indicate that lipid bodies in 
these leukocytes can function as intracellular domains 
that are both depots of esterified arachidonate and 
sites at which regulated enzymatic events relevant to 
arachidonate metabolism can occur. Lipid bodies are 
discrete intracellular structures whose formation is 
specifically inducible early, whose increased numbers 
correlate with the 'priming' responses of leukocytes to 
form enhanced amounts of both cyclooxygenase- and
lipoxygenase-derived eicosanoids and whose
inhibition of formation correlates with reduced 
synthesis of these eicosanoids. Inhibition of lipid body 
formation represents a novel pharmacologic target to 
block the formation of eicosanoid mediators of 
inflammation.
Key words: aspirin, cyclooxygenase, eosinophils, 
leukotrienes, lipid bodies, lipoxygenase, platelet-
activating factor.
INTRODUCTION
L pid bodies are non-membrane bound, lipid-rich 
cytoplasmic inclusions that form in diverse cell types.1 
W ile lipid inclusions exist in steroid-producing cells and 
pre-adipocytes and are storage sites of esterified 
cholesterol,2 in most cells little is known about the origins, 
composition or functions of lipid bodies. In limited 
numbers, lipid bodies are normal constituents of many 
cells, including neutrophils (PMN), eosinophils, mast 
cells, macrophages, endothelial cells and fibrob asts.' 
Numbers of lipid bodies typically increase when cells are 
participating in varied inflammatory or pathologic 
processes.1,3 7 In addition, lipid bodies are numerous in 
sites active in eicosanoid formation, such as the amnion 
epithelium at parturition.8 Attention to lipid bodies is 
engendered by the roles that these cytoplasmic organelles 
play in arachidonate metabolism by eosinophils and other 
leukocytes involved in inflammation. Our findings indicate 
hat lipid bodies function as intracellular domains that are 
both depots of esterified arachidonate and sites at which 
regulated enzymatic events relevant to arachidonate 
metabolism can occur. Lipid bodies constitute distinct 
structures whose formation is specifically inducible early 
(within 1h), whose increased numbers correlate with the 
'priming' responses of leukocytes to form enhanced 
quantities of both cyclooxygenase (COX)- and 
lipoxygenase (LO)-derived eicosanoids and whose 
inhibition of formation correlates with reduced synthesis 
of these eicosanoids. Inhibition of lipid body formation 
represents a new and feasible pharmacologic target to 
block the formation of eicosanoid mediators of 
inflammation. 
 We will review arachidonate metabolism pertinent to 
eicosanoid formation and current knowledge of lipid 
bodies, including their occurrence in vivo, their formation
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in vitro and their constituents, and then consider the roles 
lipid bodies may play in the heightened elaboration of 
eicosanoids by cells involved in inflammation.
ARACHIDONIC ACID METABOLISM
Oxidative metabolism of arachidonate occurs by one of 
three pathways involving COX, LO or cytochrome P450 
monooxygenase enzymes.9,10 Products of these pathways, 
termed eicosanoids, have diverse biological activities.9,11 
Arachidonate and eicosanoids function as autocrine 
signals.12 Eicosanoids are also potent paracrine 
mediators of inflammation.13 The COX pathway, present 
in cells either as constitutive COX-1 and/or as an 
inducible COX-2 enzyme, forms prostaglandins (PG) and 
thromboxanes.14-16 The 5-LO pathway, present in PMN, 
eosinophils, monocytes, mast cells and macrophages, 
forms 5-hydroxyeicosatetraenoic acid (5-HETE) and 
leukotrienes (LT).10 15-Lipoxygenase, present in some 
leukocytes, especially eosinophils, is interleukin (IL)-4-
inducible in other cells and active in inflammatory sites, 
including airways.10 The formation of eicosanoids, not 
stored preformed within cells, is tightly regulated and 
enhanced formation of eicosanoids, necessary for their 
paracrine activities, occurs in response to activating 
stimuli.10 
 Eicosanoid formation is rate-limited in part by the 
availability of free arachidonate. Within cells, arachi-
donate is not free but is incorporated within glycero-
lipids,17 especially phospholipids.18 The availability of free 
arachidonate is governed by enzymatic reactions that 
cause its acylation19 and its release from phospholipids. 
Little is known about arachidonate uptake into 
phospholipids and focus on initiation of arachidonate 
oxidative metabolism is directed towards enzymatic 
reactions that release it from phospholipids. An initial 
regulatory event involves activation of arachidonate-
releasing phospholipases (PL). Increases in intracellular 
Ca2+ and phosphorylation activate some, but not all, PL. 
The importance of some PL and their ability to prefer-
entially release eicosanoid-precursor arachidonate remain 
unsettled.20 Specific cytosolic PLA2 enzymes that are arachi-
donyl phospholipid-specific have been identified.21,22 
Specific cytosolic (cPLA2) is an 85kDa protein stimulated 
by low mmol Ca2+ and activatable by kinases, including 
mitogen-activated protein (MAP) kinases and protein 
kinase C (PKC).22-24 The cPLA2 undergoes Ca2+ dependent 
translocation from the cytosol to 'membranes'.25
Secretory PEA2 also may contribute to release of 
eicosanoid-precursor arachidonate.21 Thus, a critical 
regulatory step in eicosanoid synthesis is the regulation of 
PL activation, potentially involving MAP kinases and 
Ca2+. 
 Once liberated, arachidonate becomes available for 
oxidative metabolism, although mechanisms coupling its 
release with subsequent utilization are not clear. 
Cyclooxygenase enzymes are associated with various 
cellular membranes, including the nuclear envelope and 
endoplasmic reticulum.26 Based on the crystallographic 
structure of COX-1, COX are not transmembrane 
proteins but, rather, insert as monotopic proteins within 
one face of hydrophobic domains.27 A second regulatory 
step in eicosanoid synthesis has been identified based on 
the induction by inflammatory stimuli of COX-2 
expression,16,28,29 The 5-, 12- and 15-LO enzymes are 
cytosolic, are activated by Ca2+ and may be dependent 
on other co-factors, including phospholipids.30-32 Both S-
and 12-LO can undergo Ca2+-dependent translocation 
from the cytosol.30 For 5-LO, 5-LO-activating protein 
(FLAP) is necessary for cell expression of 5-LO activity, is a 
target for some 5-LO pathway inhibitors and apparently 
mediates translocation of cytosolic 5-LO enzyme.33 
 While translocation from the cytosol to membranes 
may facilitate interactions of cytosolic enzymes with arachi-
donate, there are increasing indications that compart-
mentalization of eicosanoid formation within cells may 
relate to the different autocrine or paracrine roles of 
eicosanoids. Thus, FLAP, 5-LO and COX can be found in 
the nuclear envelope,26,34,35 a site proximate for intracrine 
signaling. In addition, COX-1 and COX-2, coupled to 
different stimulus-initiated pathways,36 may use different 
endogenous arachidonate pools.28 Moreover, there is 
increasing recognition that cells involved in inflammatory 
responses differ from usually studied normal cells in their 
pathways of arachidonate utilization.7 At present, these 
differences are indicated by limited studies, but could 
help explain the capacities of eicosanoids to function 
separately as intracrine signals and paracrine mediators 
of infl mmation.10
LIPID BODIES
In hypothesizing a role for lipid bodies in the generation 
of eicosanoid mediators of inflammation, several issues 
are critical in validating such potential functions for these 
cytoplasmic inclusions.
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Lipid body occurrence in vivo
The ubiquity with which lipid bodies are found in vivo in 
cells associated with inflammation helps provide credi-
bility for the hypothesized functions of lipid bodies. 
However, these lipid bodies are often missed on routine 
light microscopy (they are dissolved by desiccation and 
alcohol-based hematology stains5), conventional 
histopathology or immunofluorescent localizations 
(methanol or acetone fixation solubilizes lipid bodies37). 
With lipid fixation,37 normal blood PMN and eosinophils 
contain approximately 1 and 5 lipid bodies/cell, respec-
tively, whereas PMN from patients with infections and 
eosinophils from patients with eosinophilia contain many 
more lipid bodies/cell.1,3,4,38 Induction of inflammatory 
exudates in animals with platelet-activating factor (PAF), 
specific antigen or casein 6,39 leads to increases in PMN 
lipid bodies. In vivo, increased lipid bodies in PMN 
associated with infectious, neoplastic and inflammatory 
reactions are found in tissues, blood and exudative 
effusions.4,5,38 Even in the absence of inflammation, cells 
normally active in secreting PG, such as amniotic and 
renal epithelial cells,8,40 contain increased numbers of 
lipid bodies. These in vivo findings with PMN, eosinophils 
and other cells1,4,41,42 demonstrate that lipid body 
formation, a natural event in many cell types, is a 
morphologic correlate of the cells' participation in 
inflammation or generation of eicosanoids.
Sites of esterified arachidonate
Results from electron micrograph (EM) autoradiographic 
studies have demonstrated that [3H]-arachidonate 
incorporated by human PMN,4 eosinophils,3,43 alveolar 
macrophages and mast cells, and murine and guinea pig 
peritoneal macrophages41,44 was localized at lipid bodies. 
Parallel analyses of cellular lipids3,4,41,44 and isolated 
eosinophil lipid bodies43 demonstrated that incorporated 
[3H]-arachidonate was principally esterified within 
phospholipid classes, establishing lipid bodies as sites of 
arachidonyl-phospholipid localization. Thus, lipid bodies 
function as sites of esterified arachidonate deposition in 
multiple types of leukocytes.
MECHANISMS OF LIPID BODY FORMATION
Although lipid bodies are prominent in vivo in cells 
associated with inflammatory reactions, it was unknown 
whether lipid body formation represented a physiologic
response. We have demonstrated that lipid body 
formation in leukocytes is a highly regulated cellular 
response that develops rapidly (within 1h), is elicitable by 
a restricted number of agonists and involves a cascade of 
activating steps. Leukocyte lipid body formation is 
induced by receptor-mediated PAF (but not other 
leukocyte agonists signaling through analogous G-
protein-linked receptors) acting via the 5-LO pathway,39 
by cis-unsaturated fatty acids acting via an aspirin 
(ASA)/non-steroidal anti-inflammatory drug (NSAID)-
inhibitable, but COX-1- and COX-2-independent, 
mechanism38,44 or by diglycerides.44 Both PKC and 
phospholipase C (PLC) activation39,44 are involved in lipid 
body formation, which is dependent on tyrosine 
phosphorylation and de novo protein synthesis.39 More-
over, lipopolysaccharide and hypoxia, stimuli that lead 
to heightened PG formation,45,46 elicit lipid body 
formation.47,48 These findings demonstrate that lipid body 
formation represents a deliberate, highly regulated and 
coordinated early response that generates cytoplasmic 
inclusions likely to be sites for eicosanoid synthesis.
PATHWAYS FOR INDUCTION OF LIPID BODY 
FORMATION
Platelet-activating factor-induced lipid body 
formation via a 5-lipoxygenase-dependent 
pathway
Receptor-mediated induction
Platelet-activating factor stimulated eosinophils and PMN 
lipid body formation that was dose-dependent (10-8 to 
10-6 mol/L), developed rapidly within 15min and 
increased over 1h. Platelet-activating factor-induced 
PMN and eosinophil lipid bodies were ultrastructurally 
identical to native lipid bodies.39 Platelet-activating factor 
signals via its seven transmembrane spanning receptor 
and several findings indicate that PAF induction of lipid 
body formation is receptor-mediated. First, lyso-PAF, an 
analog not binding to the PAF receptor, did not induce 
lipid bodies. Second, the PAF receptor antagonist WEB 
2086 blocked PAF-induced lipid body formation. Third, 
G-protein-linked PAF receptor signaling is pertussis toxin-
sensitive and pertussis toxin inhibited PAF-induced lipid 
body formation. Notably, in contrast to PAF, other PMN 
agonists, including leukotriene (LT) B4, IL-8, C5a and 
f rmylmethionylleucylphenylalanine (fMLP), each also 
acting via seven transmembrane spanning G-protein-
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linked receptors, failed to elicit lipid body induction. 
Thus, PAF, via a receptor-initiated pathway, was one 
specific stimulus for PMN lipid body formation.39
5-Lipoxygenase dependence of PAF-induced lipid 
body formation
Platelet-activating factor-induced lipid body formation 
was inhibited by lipoxygenase inhibitors, including the 
FLAP inhibitor MK886,33 the anti-5-LO agent zileuton, 
diethylcarbamazine (DEC) and nordihydroguiaretic acid 
(NDGA). Platelet-activating factor-induced lipid body 
formation was not inhibited by COX inhibitors. To confirm 
the 5-LO dependence of PAF-induced signaling for lipid 
body formation, we evaluated PAF induction of lipid 
bodies in PMN and macrophages from normal and 5-LO 
knock-out mice.49 Interestingly, 5-LO knock-out mice are 
known to be resistant to the lethal effects of PAF49,50 In 
PMN and peritoneal macrophages from normal mice, 
PAF stimulated lipid body formation; however, in cells 
from 5-LO-deficient mice, PAF failed to stimulate lipid 
body formation.39 Thus, a requisite role for 5-LO in PAF-
initiated induction of lipid body formation was 
established both with pharmacologic inhibitors of 5-LO 
activity and with genetically deficient 5-LO leukocytes. 
 As 5-LO activity was obligately required to mediate 
PAF-induced signaling for lipid body formation, we 
evaluated the enzymatic products of 5-LO that act to 
stimulate lipid body formation.39 Notably, LTB4 was not 
active. In addition, an LTB4 receptor antagonist (CR 105 
696) did not block PAF-induced lipid body formation, 
confirming the lack of a role for both exogenous and 
endogenous LTB4 in PAF-initiated lipid body formation. 
Instead, 5 (S)-HETE was the 5-LO product active in lipid 
body induction. 5 (S)-Hydroxyeicosatetraenoic acid 
induced dose- and time-dependent increases in PMN 
lipid body formation. 5 (S)-Hydroxyeicosatetraenoic acid 
was active at lower concentrations (10-9 to 10-7mol/L) 
than PAF and was more active than 5 (R)-HETE and 5-
oxo-ETE.39 Moreover, 5 (S)-HETE induced lipid bodies in 
cells from 5-LO knock-out mice, cells unable to generate 
their own PAF-induced 5-HETE due to the absence of 5-
LO.39 
 As with PAF itself, 5 (S)-HETE-induced lipid body 
formation was inhibited by pertussis toxin. 5-Hydro-
xyeicosatetraenoic acid has previously been shown to 
stimulate PMN by a stereospecific, G-protein-linked, 
perfussis toxin-inhibitable mechanism, suggestive of a 
specific 5-HETE receptor.51 Thus, PAF-induced lipid body
formation proceeds through a 5-LO-dependent signaling 
cascade that generates 5 (S)-HETE as an intracrine 
activator. These findings document one specific receptor-
initiated pathway involved in the rapid induction of lipid 
body formation.
cis-Fatty acid-induced lipid body formation via 
an NSAID-inhibitable, COX-independent 
pathway
Fatty acid induction
cis-Unsaturated fatty acids, oleic acid (OA) and arachi-
donic acid (AA), stimulated lipid body formation 
in a non-cytotoxic, dose-dependent (0-10mol/L) man-
ner.4,44 Lipid bodies formed rapidly, developing within 15 
min and increasing in number over 1-2h. Ultra-
structurally, cis-fatty acid-elicited lipid bodies were 
identical to native lipid bodies.4,44 Furthermore, these 
cis-fatty acid-induced lipid bodies incorporated [3H]-
arachidonate and [3H]-palmitate identically to native lipid 
bodies.4,44
Activities of cis-unsaturated fatty acids
The activities of fatty acids as lipid body inducers were 
structurally restricted.44 Fully saturated fatty acids (e. g. 
palmitate, myristate) and methyl esters of oleate and 
arachidonate were inactive.44 Unsaturated fatty acids with 
cis geometries in their double bonds were considerably 
more active than those with trans double bonds and 
ctivity as inducers of lipid body formation increased with 
an i creasing number of double bonds in C18 and C20 
fatty acids. Lipid body inducing activities of cis-fatty acids 
were not due to fatty acid-derived or-elicited oxidants.44 
The stereochemically restricted potency of fatty acids as 
lipid body inducers suggested that a specific mechanism 
was involved.
NSAID dependence of cis-fatty acid-induced 
lipid body formation
T  determine whether eicosanoids function in lipid body 
formation elicited by cis-fatty acids, potential COX and 
LO inhibitors were evaluated as inhibitors of cis-fatty 
acid-induced lipid body formation. Aspirin inhibited lipid 
body f rmation induced by cis-fatty acids in both human 
PMN and in eosinophils, as did the structurally unrelated 
NSAID indomethacin and piroxicam. Moreover, sodium 
salic late (which does not substantially inhibit COX) was
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as potent as ASA in inhibiting lipid body formation elicited 
by cis-fatty acids, suggesting that NSAID inhibition of lipid 
body formation was independent of COX inhibition. 
Neither ASA, indomethacin nor sodium salicylate inhibited 
[14C]-AA uptake by human PMN stimulated by AA, 
indicating that these agents were not acting by diminishing 
fatty acid uptake. The lipoxygenase inhibitors zileuton, 
NDGA, DEC and MK886, did not inhibit cis-fatty acid-
induced lipid body formation, in contrast to their inhibition 
of PAF-induced lipid body formation. Thus, ASA and 
varied NSAID, but not LO inhibitors, inhibited cis-fatty 
acid-induced lipid body formation.38 
 We next evaluated whether the inhibitory actions of 
ASA and NSAID were attributable to COX inhibition and 
several findings demonstrated that inhibition of cis-fatty 
acid induced lipid body formation by these agents was 
not COX-dependent.38 First, the inhibition of lipid body 
induction by sodium salicyclate, an anti-inflammatory 
agent of uncertain action as it is unable to acetylate and 
inhibit COX enzymes, suggested a lack of dependence 
on COX inhibition. Second, cis-fatty acids, AA and OA all 
induced lipid body formation in macrophages from COX-
1 and COX-2 genetically deficient mice identically as in 
macrophages from wild-type mice. Third, NSAID 
(indomethacin, sodium salicylate and NS-398) inhibited 
lipid body formation stimulated by both OA and AA in 
macrophages from COX-1 and COX-2 mice. Interesti-
ngly, NS-398, a nominally specific COX-2 inhibitor,52 
blocked lipid body formation in macrophages from wild-
type and COX-1- and even COX-2-deficient mice, 
indicating that the anti-inflammatory actions of NS-398 
are not restricted to COX-2 inhibition, but may also be 
based on inhibiting lipid body formation. 
 Thus, ASA and NSAID, via a COX-independent 
mechanism, inhibit cis-fatty acid-induced lipid body 
formation and this finding, together with related data on 
the suppression of eicosanoid formation presented later, 
expands the range of anti-inflammatory actions of these 
agents.38
1-Oleyl-2 -acetylglycerol-induced pathway of 
lipid body formation
Diglycerides prime PMN for enhanced eicosanoid 
production.53 We have demonstrated that the cell-
permeable diglyceride, 1-oleyl-2-acetylglycerol (OAG), 
stimulated dose- and time-dependent lipid body 
formation in PMN.44 1-Oleyl-2-acetylglycerol-induced 
PMN lipid body formation was not inhibited by LO
inhibitors or by NSAID. Hence, the rapid induction of lipid 
body formation in leukocytes by OAG did not involve 
ei her of the initial signaling pathways used by PAF (5-LO-
depen ent) or cis-fatty acids (ASA/NSAID-inhibitable).
INTRACELLULAR SIGNALING FOR LIPID BODY 
FORMATION
Having identified three specific classes of agonists and 
their initial pathways for initiation of lipid body induction, 
we further evaluated downstream intracellular signaling 
pathways involved in lipid body formation, including PKC 
and PLC.
Protein kinase C mediation
1-Oleyl-2-acetylglycerol and cis-fatty acids activate PKC 
in PMN and other cells and may differentially activate 
PKC isozymes.54 That the activities of OAG and cis-fatty 
acids as well as PAF in inducing PMN lipid body 
formation were mediated in part by PKC activation was 
demonstrated with both PKC agonists and inhibitors. 
Other PKC activators, two PKC activating phorbol esters 
(phorbol myristate acetate (PMA), but not an inactive 
phorbol, stimulated lipid body formation.44 Furthermore, 
PKC inhibitors 1-hexadecyl-2-O-methyl-glycerol, H-7, 
staurosporine and chelerythrine, blocked PMN lipid body 
formation elicited by diglyceride (OAG) and phorbol 
esters,44 by cis-fatty acids (AA and OA)44 and by PAF and 
5-HETE.39 Protein kinase C induces many changes in lipid 
metabolism in PMN (e. g. increases in diglycerides, 
phospholipid turnover and synthesis).55,56 Our findings 
indicate that PKC-induced alterations in lipid metabolism 
occur in concert with what has been overlooked in 
biochemical studies, namely specific cellular responses 
that coordinately organize mobilized lipids and their 
associated proteins within the discrete, structurally 
defined domains of lipid bodies. Thus, PKC is centrally 
involved in lipid body formation elicitable with each of the 
three classes of lipid body inducers.
Phospholipase C mediation
In addition to PKC, PLC activation is involved in signaling 
lipid body formation, as evidenced by the actions of the 
two PLC inhibitors D609 and U73122. These PLC 
inhibitors suppressed lipid body formation induced by cis-
fatty acids, PAF, OAG and 5-HETE.39 With PMN, 
combinations of PKC and PLC inhibitors have been 
cytotoxic and we have not been able to determine
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whether blockade of both pathways is sufficient to 
completely inhibit elicited lipid body formation. As neither 
PKC nor PLC inhibitors completely suppressed induced 
lipid body formation, it is likely that PKC and PLC mediate 
parallel pathways that signal events involved in lipid body 
formation.
INTRACELLULAR MECHANISMS FOR LIPID BODY 
FORMATION
In addition to the signaling mechanisms noted earlierthat 
are involved in lipid body formation, other fundamental 
biochemical processes are involved.
Tyrosine kinase activation
Tyrosine kinases (TK) are involved in the activation of 
arachidonate mobilization and eicosanoid formation.57 
Agents that inhibit TK, namely genistein and herbimycin 
A, inhibit the induction of lipid body formation elicited by 
PAF,39 cis-fatty acids and OAG.
De novo protein synthesis
To evaluate whether new transcriptional and translational 
activity is required during the induction of lipid body 
formation in PMN, inhibitors of these steps were 
evaluated. Two inhibitors of translation, cycloheximide 
and puromycin, and a transcription inhibitor, actinomycin 
D, inhibited OAG-induced lipid body formation in PMN. 
Similarly, cycloheximide and actinomycin D inhibited lipid 
body induction stimulated by both PAF39 and cis-fatty 
acids. These findings indicate that the stimulated 
induction of lipid body formation depends on new mRNA 
and protein synthesis. Thus, there must be activation of 
early response genes involved in the formation of lipid 
bodies and lipid bodies represent early response 
structures in cells.
SUMMARY OF DEFINED SIGNALING PATHWAYS 
FOR LIPID BODY FORMATION
In defining the mechanisms of lipid body induction in 
leukocytes, we have identified three classes of signaling 
agents and have helped determine the intracellular 
signaling pathways used by them. As shown schematic-
ally in Fig. 1, one pathway is initiated by receptor-
mediated PAF signaling via 5-LO activation to generate 
5-HETE, which then signals via a likely receptor-
dependent mechanism. The second pathway initiated by
cis-fatty acids is ASA/NSAID-inhibitable, but COX-
independent. Diglyceride (OAG) constitutes a third 
defined initiating signal. For all three pathways, common 
downstream signaling requires PKC and PLC activation, 
TK activity and new mRNA and protein synthesis. Thus, 
the formation of lipid bodies arises from a highly 
coordinated series of sequential signaling and activating 
responses in leukocytes.
LIPID BODY FORMATION IN VIVO
To complement the in vitro studies that delineated 
pathways for lipid body formation, additional findings 
documented that lipid body formation accompanies 
inflammatory reactions in vivo. As PAF stimulates lipid 
body formation in PMN via a 5-LO-dependent signaling 
cascade, we evaluated whether administration of PAF 
in vivo would similarly generate leukocyte lipid bodies 
and whether this would be 5-LO-dependent.39 Platelet-
activating factor (1mg) was administered into the pleural 
space of mice. Instillation of PAF resulted in little change 
in numbers of resident macrophages after 1h in either 
wild-type or 5-LO knockout mice but, as expected, 
dramatically increased pleural cavity PMN from approxi-
mately 104 to 7×105/cavity in wild-type mice. In 5-LO
knockout mice, the PMN influx after PAF was virtually 
absent. Intrapleural PAF significantly increased lipid body 
numbers in resident pleural macrophages and in 
recruited PMN. Moreover, this in vivo induction of lipid 
bodies in response to PAF was absent in pleural macro-
ph ges and in PMN from 5-LO-deficient mice. Thus, PAF 
stimulates lipid body formation via a 5-LO-dependent 
sequence in vivo as well as in vitro.39
ENZYMATIC MOBILIZATION OF ARACHIDONATE 
FROM LIPID BODIES
If lipid bodies constitute reservoirs of esterified arachi-
donate, then that archidonate must be liberated 
by specific PL. The freed arachidonate must either e 
translocated to sites where eicosanoid-forming enzymes 
act or these eicosanoid-forming enzymes must reside 
t or be translocated to lipid bodies. As the locali 
zation of arachidonate-mobilizing and -metabolizing 
enzymes at lipid bodies would provide critical novel 
information indicative of roles of lipid bodies in 
eicosanoid formation, we have actively sought evidence 
that these enzymes are present at lipid bodies. We have 
now established that all major proteins required for
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Fig. 1 Cellular signaling pathways for lipid body formation.
eicosanoid formation, including COX and LO 
themselves, are localized to lipid bodies.
SITES OF EICOSANOID-FORMING ENZYME 
LOCALIZATION
We have localized COX to lipid bodies in several cell 
types, including 3T3 fibroblasts (PF Weller et al., unpubl. 
obs., 1996). Fibroblasts treated with rabbit anti-COX 
antisera, biotinylated second antibody and avidin-
biotin complexed (ABC)-glucose oxidase or -alkaline 
phosphatase demonstrated diffuse perinuclear and 
endoplasmic reticulum anti-COX staining, fully consistent 
with that noted previously,26,58,59 as well as distinct 
punctate anti-COX staining of lipid bodies (PF Weller 
et al., unpubl, obs., 1996). 
 We corroborated lipid body localization of COX with 
immunogold EM and demonstrated that a variety of cells 
obtained from human airways by bronchoalveolar lavage 
contain COX in their lipid bodies.60 Lipid bodies in 
alveolar macrophages incorporated [3H]-AA and 
exhibited immunogold staining with an anti-COX 
monoclonal antibody (mAb) but not a control-irrelevant
mAb.60 With similar techniques, we localized COX by EM 
immunogold to lipid bodies in human eosinophils,61 
human lung mast cells, alveolar macrophages, type II 
pneumocytes and neutrophils,60,62 murine 3T3 fibroblasts61 
and guinea pig peritoneal macrophages and line 10 
hepatocarcinoma cells.63 In these studies, control, 
negative staining with irrelevant mAb or with affinity-
absorbed anti-COX mAb confirmed the specificity of 
immunogold localization of COX to lipid bodies. Thus, 
our ultrastructural studies, which previously localized 
[3H]-AA to lipid bodies by EM autoradiography in a 
diversity of cells3,4,41,43,44,62 now provide supporting data 
tha  COX is present in lipid bodies. 
 With similar approaches, we can localize other 
arachidonate-releasing and LT-synthesizing enzymes to 
leukocyte lipid bodies (PF Weller et al., unpubl. obs., 
1997). These novel findings support the capacity of lipid 
b di s to serve as sites for local eicosanoid formation. 
The co-compartmentalization of arachidonyl-phospho-
lipids, cPLA2, its activating kinases and eicosanoid-
forming enzymes provides in one site an efficient means 
to regulate arachidonate release and couple it directly 
with oxidative metabolism to form eicosanoids.
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USE OF LIPID BODY DERIVED ARACHIDONATE 
FOR EICOSANOID SYNTHESIS
We have correlated lipid body induction with enhanced, 
primed synthesis of eicosanoids. Our hypothesis predicts 
that induction of lipid bodies will lead to enhanced 
formation of both COX- and LO-derived eicosanoids. We 
have extensively tested this prediction. All lipid body 
inducing stimuli lead to enhanced eicosanoid genera-
tion. Moreover, increasing lipid body numbers correlate 
directly with increasing levels of LO- and COX-derived 
eicosanoids generated by leukocytes. Human eosinophils 
or PMN were pre-incubated for 1h with concentrations 
of distinct stimuli to induce lipid body formation: OA (a 
cis-fatty acid not an eicosanoid substrate), AA, OAG or 
PAF. Lipid bodies were enumerated, and replicate 
leukocytes were challenged with submaximal (0.25-0.5 
mol/L) calcium ionophore A23187. Increasing concen-
trations of each of the four stimuli led to increasing lipid 
body numbers and, correspondingly, increasing LTC4 
production.38,39 The increasing amounts of LTC4 formed 
paralleled and statistically correlated with numbers of 
lipid bodies induced with each of the four stimuli. 
 Analogously, after leukocyte lipid bodies were induced 
with cis-fatty acids, magnitudes of LTB4 and PGE2 
production correlated with PMN lipid body numbers and 
amounts of LTC4 correlated with eosinophil lipid body 
numbers.38 Arachidonic acid, as well as OA, dose-
dependently induced concordant increases in both lipid 
body numbers and priming for enhanced LTB4, PGE2 and 
LTC4 production. Increased numbers of AA- and OA-
induced lipid bodies in both cell types correlated with 
the increased quantities of each eicosanoid generated by 
the primed leukocytes. Notably, stimulation of leukocytes 
with OA, not itself an eicosanoid precursor fatty acid, 
led to increments in the production of each eicosanoid 
that quantitatively paralleled the incremental increases 
in lipid body numbers (PGE2 r=0.99, P<0.01; LTB4 
r=0.99, P<0.01; LTC4 r=0.95, P<0.05). Thus, the 
capacity of two different leukocyte types to generate 
greater quantities of COX and LO pathway derived 
eicosanoids correlated with levels of lipid bodies in these 
cells.38 
 With PAF as a stimulus we have evaluated both the 
dose and time dependence of lipid body induction and 
priming for enhanced eicosanoid release in human 
PMN.39 The PMN were incubated with increasing 
concentrations of PAF (10-8 to 10-6mol/L) for 5 min or 
1h. After incubation, lipid bodies were enumerated and 
replicate leukocytes were stimulated with submaximal
A23187 (0.5μmol/L). Platelet-activating factor induced
dose-dependent increases in PMN lipid body numbers 
after 1h, but not as early as 5min after stimulation. 
Incubation with PAF for only 5min failed to prime PMN 
for enhanced LTB4 or PGE2 production. However, after 
1h of PAF stimulation, significant dose-dependent 
priming for enhanced production of both LTB4 and PGE2 
was noted. Platelet-activating factor induced 5.5- and 
2.8-fold increases in the production of LTB4 and PGE2, 
respectively, at the highest PAF concentration (10-6 
mol/L). Furthermore, there were statistically significant, 
positive correlations between the PMN content of lipid 
bodies and priming for enhanced LTB4 (r=0.986, 
P<0.001) and PGE2 (r=0.971, P<0.001) 
generation.39 Thus, there were both dose- and time-
dependent correlations between lipid body formation 
and enhanced eicosanoid formation, further indicating 
that lipid bodies contribute to eicosanoid formation. 
 In all of these studies with each stimulus for lipid body 
induction, the quantities of produced eicosanoids, both 
COX- and LO-derived, demonstrated statistically 
significant correlations with the numbers of induced lipid 
bodies. While this is correlative and not alone definitive 
proof that lipid bodies are sites of augmented eicosanoid 
synthesis, these findings are fully supportive of potential 
oles for lipid bodies in enhanced eicosanoid production. 
 As the induction of COX-2 by inflammatory stimuli 
represents one inducible mechanism to augment 
prostanoid production, we determined which COX was 
responsible for enhanced PG production by evaluating 
the effects of COX-1 or COX-2 deficiency on priming.38 
Primed COX-2-deficient macrophages were found to be 
indistinguishable from wild-type cells in both lipid body 
and PGE2 formation, indicating that COX-2 does not 
h ve a role in enhanced PG production. However, 
primed COX-1-deficient macrophages demonstrated 
severely diminished levels of PGE2, identifying COX-1 as 
the enzyme responsible for enhanced PGE2 production 
induced early in AA-primed macrophages. As the 
i duction of COX-2 expression by stimuli including LPS57 
requires up to 48h, our findings with lipid bodies identify 
lipid body induction as a more rapid and COX-2-
independent means to increase production of both COX-
and LO-derived eicosanoids.
CONCOMITANT INHIBITION OF LIPID BODY 
INDUCTION AND EICOSANOID FORMATION
If the hypothesis that lipid bodies have roles in 
augmented eicosanoid formation is valid, then the
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inhibition of lipid body formation should result in 
suppressed eicosanoid formation. We have tested this 
prediction and have validated it with several types of 
inhibitors.
Aspirin inhibition of induction of enhanced 
eicosanoid generation
We evaluated whether aspirin (ASA) inhibition of lipid 
body formation would affect cis-fatty acid-induced 
priming for enhanced production of both COX- and 
lipoxygenase-derived eicosanoids.38 Aspirin pretreatment 
inhibited PGE2 production by human PMN and 
eosinophils in vehicle- and cis-fatty acid-stimulated 
leukocytes, but this ASA inhibition of prostanoid 
production may be due solely to ASA inhibition of COX. 
In contrast, ASA is devoid of direct inhibitory effects on LO 
in leukocytes and platelets.64-66 We have demonstrated 
that ASA significantly inhibits AA- and OA-induced 
priming for enhanced production of 5-LO-derived LTB4 
by PMN and LTC4 by eosinophils and that sodium 
salicylate similarly inhibited cis-fatty acid-induced 
priming for enhanced LTB4 production by PMN. Aspirin 
was not acting to block pathways of AA mobilization or 
metabolism activated by calcium ionophore, as aspirin 
failed to inhibit calcium ionophore-induced LTB4 and 
LTC4 production in cells not prestimulated with cis-fatty 
acids and was not inhibiting eicosanoid export (no 
residual intracellular eicosanoids were detectable). The 
inhibition by aspirin of priming for enhanced eicosanoid 
production correlated with its ability to inhibit cis-fatty 
acid-induced lipid body formation.38
CYCLOHEXIMIDE-ACTINOMYCIN D INHIBITION 
OF ENHANCED EICOSANOID GENERATION
Because the protein synthesis inhibitors actinomycin D 
and cycloheximide were effective in blocking lipid body 
formation induced by PAF and lipid body numbers 
correlated with enhanced eicosanoid formation, we 
examined whether protein synthesis inhibitors would 
inhibit PAF-induced priming for eicosanoid production.39
Pretreatment of PMN With actinomycin D (1μmol/L) or
cycloheximide (1μmol/L) inhibited not only PAF-induced
lipid body formation, but also priming for enhanced LTB4 
and PGE2 production.39 Protein synthesis inhibitors were 
not acting to block pathways of arachidonate release or 
metabolism that are activated by calcium ionophore, as 
actinomycin D and cycloheximide failed to inhibit 
calcium ionophore-induced LTB4 and PGE2 production in 
cells not prestimulated with PAF.39
 Thus, inhibitors of lipid body induction, whether they 
be ASA/NSAID blocking OA- or AA-induced lipid body 
formation or inhibitors of mRNA and protein synthesis, 
also inhibited the enhanced production of both COX-
and LO-derived eicosanoids. This provides additional 
support for the hypothesized roles of lipid bodies as 
inducible sites active in the enhanced generation of 
eicosanoid mediators of inflammation. Moreover, the 
capacity of inhibitors of lipid body induction to block 
eicosanoid formation identifies a novel target for anti-
inflammatory drug action. Notably, the suppression by 
ASA and NSAID of lipid body production and of LT and 
PG production, by a COX-independent mechanism, 
expands our understanding of the anti-inflammatory 
actions of these drugs. Aspirin and NSAID block cis-fatty 
acid-induced lipid body formation and concomitantly 
inhibit formation of both COX- and LO-derived 
eicosanoids.
RELEVANCE OF LIPID BODIES TO EICOSANOID 
PRODUCTION BY INFLAMMATORY CELLS
If lipid bodies have specific roles in contributing to 
eicosanoid mediator formation in inflammation, lipid 
bodies may provide distinct advantages.
As membrane-sparing domains
Eicosanoids derive from arachidonyl-phospholipids 
assumed to reside in membranes, but which membranes 
and, indeed, whether it is membranes that serve as 
depots of precursor arachidonate are unknown. In one 
study, cells lost their capacity to form PGE2 after 
deprivation of exogenous arachidonate for 24-48h.67 As 
total cellular arachidonate and relevant enzymes 
remained normal, arachidonate depletion from an 
unidentified cellular pool was hypothesized.67 Under the 
conditions used, lipid bodies would most likely have been 
depleted.68 Another consideration concerning membrane 
structure is pertinent. Using lipid bodies, not membranes, 
as a source of eicosanoid-precursor arachidonate 
obviates excessive membrane perturbation when 
quantities of arachidonate are removed from membrane 
phospholipids. Hence, relatively small quantities of 
arachidonate may be liberated from membranes when 
that arachidonate forms autocrine eicosanoids, as 
elicited by signal-transducing mechanisms within 
membranes, whereas larger amounts of arachidonate 
needed for forming eicosanoid paracrine mediators 
could be derived from lipid body stores.
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As a basis for leukocyte priming
In studies of PMN there has been an apparent paradox. 
In response to ionophore A23187, PMN generate large 
quantities of 5-HETE and LTB4, whereas more natural, 
receptor-mediated stimulation (e. g. fMLP) routinely elicits 
little eicosanoid formation53,69 unless PMN are first 
'primed'. 'Priming' consists of pre-incubating PMN with 
OAG, PAF, arachidonate, PMA or lipopolysaccharide 
(LPS)45,53,69 Of note from our studies, these same priming 
agents in the concentrations and time periods used, 
would induce abundant lipid body formation.38,39,44 
Analogously, pre-incubating cells with 10-50mol/L 
arachidonate prior to stimulation (as done nominally 
to provide ample substrate) also stimulates lipid body 
formation.38 Priming agents similarly augment eicosanoid 
formation by A23187-stimulated PMN.38,39,70,71 Thus, the 
capacity of PMN to release eicosanoids in response to 
physiologic stimuli could be correlated with their content 
of lipid bodies and 'priming' for eicosanoid release could 
be based, at least in part, on lipid body induction. 
 We have documented a relationship between lipid 
body formation and primed responsiveness for aug-
mented eicosanoid formation. With each class of lipid 
body inducer (PAF, OAG, cis-fatty acids, LPS), we have 
now established that numbers of induced lipid bodies 
correlate with magnitudes of enhanced COX- and LO-
derived eicosanoids. Moreover, inhibition of lipid body 
induction with various inhibitors correlates with sup-
pression of priming for enhanced eicosanoid generation. 
Aspirin inhibition of OA-induced lipid body formation 
even suppresses generation of 5-LO (not itself ASA-
inhibitable)-derived LT. Thus, prior induction of lipid body 
formation is associated with the capacity for primed 
generation of eicosanoids, and inhibition of lipid body 
formation is associated with diminished capacity to form 
both COX- and LO-derived eicosanoids.
As an inducible early mechanism to enhance 
inflammation
In contrast to normal leukocytes studied ex vivo, in vivo it 
is cells associated with inflammation, those likely to con-
tain many lipid bodies, that, are producing quantities of 
eicosanoids.7 For instance, PMN from casein-elicited 
rodent peritoneal exudates produced more LTB4 than did 
normal PMN72 and activated 'hypodense' human eosino-
phils (which contain many lipid bodies3) form more LTC4 
than normal eosinophils.73 In leukocytes and other cells
associated with inflammation, the mobilization of arachi-
donate for eicosanoid formation may differ from that 
studied in more readily obtainable normal blood leuko-
cytes.7 The capacity of leukocytes to rapidly form lipid 
bodies in association with inflammatory processes 
provides a means by which these cells can rapidly 
develop specialized intracellular domains that augment 
their capability to generate eicosanoid mediators of 
inflammation. In comparison with the induction of COX-
2, which occurs over 2-48h and augments only PG 
production, induction of lipid body formation develops 
within 1h and is associated with enhanced formation of 
both PG and LT. Thus, the induction of lipid body 
formation is a distinct, early developing response that 
constitutes a means to augment the generation of diverse 
eicosanoid mediators of inflammation.
As a site for cytokine actions
A novel finding that adds yet another potential dimension 
to the functions of lipid bodies is the recognition that lipid 
bodies are sites of localization of some cytokines, notably
tumor necrosis factor(TNF)-α.74 Our initial indications
that lipid bodies may be sites of localization of the
cytokine TNF-α arose during studies of human eosino-
phils,75 in which immunolocalization at the light 
microscopic level demonstrated lipid body staining with
antiTNF-α mAb. To confirm this finding and to evaluate
its pertinence in vivo we used ultrastructural immunogold
localization of TNF-α to evaluate infiltrating inflammatory
leukocytes in colonic lesions of Crohn's disease.74 
Eosinophils, mast cells, neutrophils, macrophages, 
epithelial cells and other leukocytes exhibited specific
immunogold staining for TNF-α. in sites uniformly
included lipid bodies.74 Controls, including irrelevant
mAb and anti-TNF-α mAb immunoabsorbed with solid-
phase TNF-α, were negative.74 While TNF-α was also
located in other sites within these cells, in each of the 
leukocytes present in sites of Crohn's colitis, lipid body 
domains exhibited specific immunogold localization for
TNF-α.74 The lipid body localization of TNF-α, initially
recognized as cachectin due to its lipolytic activities, is
intriguing because of the role that TNF-α. may play in
eicosanoid metabolism.
SUMMARY
Lipid bodies represent specialized intracellular domains. 
Their prominence in vivo in natural and experimental
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inflammation supports their relevance to natural 
inflammation. In addition, the specificities of the cellular 
signaling pathways that rapidly induce lipid body 
formation indicate that their formation is a deliberate and 
well-regulated process. The dependence of lipid body 
induction on de novo mRNA and protein synthesis makes 
lipid bodies structural analogs and, probably, in part 
products of early response genes. These structures contain 
esterified eicosanoid-precursor arachidonate. An 
arachidonate-releasing phospholipase (cPLA2) and its 
activating kinases (MAP kinases and PKC) are present and 
active at lipid bodies and eicosanoid-forming enzymes 
(COX and 5- and 15-LO) localize to lipid bodies. Lipid 
body numbers correlate with priming for enhanced 
eicosanoid synthesis and inhibition of lipid body formation 
is associated with loss of this priming. Thus, the 
heightened presence of lipid bodies in cells likely to be 
generating eicosanoids as part of inflammatory reactions 
is a reflection of the functions of lipid bodies as dynamic, 
rapidly inducible, specialized intracellular domains with 
roles in the metabolic transformation of arachidonate into 
paracrine mediators of inflammation.
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